Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity

Alberto Moreno; Kelly Manning; Maryam I. Azeem; Ajay K. Nooka; Madison Ellis; Renee Julia Manalo; Jeffrey M. Switchenko; Bushra Wali; Jonathan L. Kaufman; Craig C. Hofmeister; Nisha S. Joseph; Sagar Lonial; Kavita M. Dhodapkar; Madhav V. Dhodapkar; Mehul S. Suthar

doi:10.1038/s41541-024-00999-6

npj Vaccines (Oct 2024)

Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity

Alberto Moreno,
Kelly Manning,
Maryam I. Azeem,
Ajay K. Nooka,
Madison Ellis,
Renee Julia Manalo,
Jeffrey M. Switchenko,
Bushra Wali,
Jonathan L. Kaufman,
Craig C. Hofmeister,
Nisha S. Joseph,
Sagar Lonial,
Kavita M. Dhodapkar,
Madhav V. Dhodapkar,
Mehul S. Suthar

Affiliations

Alberto Moreno: Emory Vaccine Center, Emory University
Kelly Manning: Emory Vaccine Center, Emory University
Maryam I. Azeem: Department of Hematology/Medical Oncology, Emory University
Ajay K. Nooka: Department of Hematology/Medical Oncology, Emory University
Madison Ellis: Emory Vaccine Center, Emory University
Renee Julia Manalo: Department of Hematology/Medical Oncology, Emory University
Jeffrey M. Switchenko: Winship Cancer Institute
Bushra Wali: Emory Vaccine Center, Emory University
Jonathan L. Kaufman: Department of Hematology/Medical Oncology, Emory University
Craig C. Hofmeister: Department of Hematology/Medical Oncology, Emory University
Nisha S. Joseph: Department of Hematology/Medical Oncology, Emory University
Sagar Lonial: Department of Hematology/Medical Oncology, Emory University
Kavita M. Dhodapkar: Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University
Madhav V. Dhodapkar: Department of Hematology/Medical Oncology, Emory University
Mehul S. Suthar: Emory Vaccine Center, Emory University

DOI: https://doi.org/10.1038/s41541-024-00999-6
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

Published in npj Vaccines

ISSN: 2059-0105 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.nature.com/npjvaccines/

About the journal